TD Cowen Issues Positive Forecast for McKesson (NYSE:MCK) Stock Price

McKesson (NYSE:MCK) had its price objective upped by TD Cowen from $1,006.00 to $1,200.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts also recently issued reports on MCK. UBS Group upped their price objective on shares of McKesson from $1,080.00 to $1,200.00 and gave the company a “buy” rating in a research note on Friday, October 16th. Citigroup raised their price target on McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Evercore reiterated an “outperform” rating and set a $950.00 price objective (down from $1,000.00) on shares of McKesson in a report on Thursday, August 6th. Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, September 4th. Finally, Robert W. Baird set a $1,015.00 target price on McKesson in a research report on Thursday, August 6th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,023.24.

McKesson Trading Up 0.6%

NYSE:MCK opened at $1,075.38 on Thursday. The company has a market capitalization of $125.38 billion, a P/E ratio of 27.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.27. The firm has a 50-day moving average price of $934.72 and a two-hundred day moving average price of $866.92. McKesson has a twelve month low of $723.68 and a twelve month high of $1,121.50.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating the consensus estimate of $10.72 by $0.96. McKesson had a net margin of 1.12% and a negative return on equity of 235.48%. The business had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. During the same period in the prior year, the business earned $9.86 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. On average, equities research analysts predict that McKesson will post 44.71 earnings per share for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson’s payout ratio is currently 9.67%.

Insiders Place Their Bets

In other news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the transaction, the chief accounting officer directly owned 521 shares in the company, valued at approximately $464,445.45. This trade represents a 17.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of McKesson stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,812 shares of company stock valued at $1,794,182 in the last quarter. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On McKesson

Several large investors have recently added to or reduced their stakes in MCK. Secure Asset Management LLC grew its holdings in McKesson by 484.8% in the 2nd quarter. Secure Asset Management LLC now owns 2,123 shares of the company’s stock worth $1,604,000 after buying an additional 1,760 shares in the last quarter. Royal London Asset Management Ltd. grew its position in McKesson by 1.1% in the 2nd quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock valued at $84,809,000 after buying an additional 1,216 shares in the last quarter. BayBridge Capital Group LLC grew its position in McKesson by 268.0% in the 2nd quarter. BayBridge Capital Group LLC now owns 1,943 shares of the company’s stock valued at $1,468,000 after buying an additional 1,415 shares in the last quarter. Benchmark Investment Advisors LLC bought a new stake in shares of McKesson during the 2nd quarter worth about $441,000. Finally, Summit Global Investments acquired a new stake in McKesson in the second quarter worth approximately $1,159,000. 85.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: For fiscal Q2 2027, McKesson reported adjusted EPS of $11.68 versus analyst estimates near $10.70, while revenue of about $111 billion also topped expectations and grew roughly 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes, operating improvements and GLP-1 momentum. The company also completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services footprint. Earnings Call Highlights: Raised Guidance, GLP-1 Momentum
• Positive Sentiment: Several firms raised targets, including TD Cowen, Leerink Partners and Evercore ISI to $1,200; Deutsche Bank raised its target to $1,120. RBC also praised McKesson’s execution, and a Seeking Alpha analysis described normalized earnings as supporting an attractive valuation. TD Cowen Raises Price Target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged trading plan to cover tax withholding on vested equity awards; he retained 5,064 shares, making the transaction less indicative of a change in business outlook. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating came with a $965 target—below the recent share price—suggesting limited upside in that firm’s view despite its target increase. RBC on McKesson’s Execution

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.